Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Intercept hit hard as NASH trial misses the mark

Supreme court throws Novartis a lifeline for Gilenya defense

Frontiers Health Steering Committee spotlight: Eugene Borukhovich

Babylon hires Andrew Hine to spearhead overseas expansion

Merck defends blockbuster Januvia franchise from patent challenge

Tresiba

Novo Nordisk

Diabetes/ News/ News/ News/ Novo Nordisk/ Patients/ R&D/ Top pharmaceutical companies/ Top stories

Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba

Piotr Wnuk Diabetes, Novo Nordisk, Sanofi, Toujeo, Tresiba 0 Comment

Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control

X

Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba

https://pharmaphorum.com/news/tresiba-improved-sugar-control-decreased-hypos/

Tresiba

News/ UK & Europe/ US

Novo’s Tresiba primed for key ‘hypo’ label update in EU

Richard Staines Diabetes, Fiasp, Novo Nordisk, safety, Sanofi, Tresiba 0 Comment

Fast-acting insulin also approved in US

X

Novo’s Tresiba primed for key ‘hypo’ label update in EU

https://pharmaphorum.com/news/novos-tresiba-gets-key-hypo-label-update-eu/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Name change for Johnson & Johnson offshoot to Kenvue
Biogen, Eisai say lecanemab has aced phase 3 Alzheimer's study
Getting approval will only be the first challenge facing lecanemab
Almirall joins IL-2 push in autoimmunity with $507m Simcere deal
FDA clears Dupixent as first drug for rare skin disorder

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com